Skip to main content

BioAtla Inc

For the period ended Dec 31, 2023. Filed Mar 26, 2024.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 26, 2024

BCAB$1.74-44.7%Stored close · as of Aug 28, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

BioAtla, Inc.
Date: March 26, 2024By:/s/ Jay M. Short, Ph.D.
Jay M. Short, Ph.D.
Chief Executive Officer(Principal Executive Officer and Authorized Signatory)

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Jay M. Short, Ph.D. and Richard A. Waldron as his or her true and lawful attorneys-in-fact, and each of them, with full power of substitution, for him or her in any and all capacities, to sign any amendments to this Annual Report on Form 10-K and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact, and either of them, or his or their substitute or substitutes may do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report on Form 10-K has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

SIGNATURETITLEDATE
/s/ Jay M. Short, Ph.D.Jay M. Short, Ph.D.Chief Executive Officer and Director(Principal Executive Officer)March 26, 2024
/s/ Richard A. WaldronRichard A. WaldronChief Financial Officer(Principal Financial and Accounting Officer)March 26, 2024
/s/ Scott SmithScott SmithDirectorMarch 26, 2024
/s/ Lawrence Steinman, M.D.Lawrence Steinman, M.D.DirectorMarch 26, 2024
/s/ Mary Ann Gray, Ph.D.Mary Ann Gray, Ph.D.DirectorMarch 26, 2024
/s/ Susan Moran, M.D.Susan Moran, M.D.DirectorMarch 26, 2024
/s/ Sylvia McBrinnSylvia McBrinnDirectorMarch 26, 2024
/s/ Edward WilliamsDirectorMarch 26, 2024
Edward Williams
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.